Canine Inflammatory Bowel Disease: Welfare Management

Key Welfare Considerations

• Canine IBD encompasses lymphoplasmacytic, eosinophilic, and granulomatous forms affecting small or large intestine.
• Chronic vomiting, diarrhoea, weight loss, and lethargy significantly impair welfare quality of life.
• Protein-losing enteropathy (PLE) from severe IBD causes hypoalbuminaemia and oedema welfare emergencies.
• Food-responsive enteropathy (FRE) resolves with dietary management — welfare improvement without immunosuppression.
• Novel protein diets or hydrolysed protein diets are the first-line welfare intervention for dietary-responsive cases.
• 6-8 week dietary trial is required before concluding dietary management has failed for welfare.
• Prednisolone is the cornerstone of immunosuppressive welfare treatment for true IBD.
• Budesonide provides colonic anti-inflammatory welfare benefit with reduced systemic absorption.
• Azathioprine or chlorambucil are steroid-sparing welfare options for refractory or severe cases.
• Cobalamin (vitamin B12) deficiency from IBD causes welfare neurological and metabolic effects requiring supplementation.
• Folate deficiency from proximal small intestinal IBD welfare impacts require dietary supplementation.
• The faecal microbiome is profoundly altered in canine IBD — dysbiosis contributes to welfare disease perpetuation.
• Probiotics and faecal microbiota transplantation show emerging welfare benefit in canine IBD management.
• Regular welfare monitoring through body weight, clinical assessment, and serum proteins guides treatment adjustment.
• Long-term welfare outcomes vary — many dogs achieve good quality of life with appropriate management.